Physician profile
Smita Biswas
NPI 1982751103
$1,279.65
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $148 · 2021: $301 · 2022: $211 · 2023: $241 · 2024: $46.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $187 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $187.21 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $185.11 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $176.17 | 2023-2024 | Veozah |
| Daiichi Sankyo INC. | $142.92 | 2021-2023 | Injectafer |
| Evofem Biosciences, INC. | $141.96 | 2021-2023 | Phexxi |
| Myovant Sciences INC. | $100.57 | 2021-2022 | |
| Avion Pharmaceuticals | $81.96 | 2019-2022 | |
| Coopersurgical, INC. | $68.28 | 2019 | |
| Allergan, INC. | $64.28 | 2019 | |
| Mayne Pharma Commercial LLC | $62.63 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $50.76 | 2019-2021 | |
| Lupin INC. | $43.00 | 2019-2020 | |
| Hologic Sales and Service, LLC | $37.61 | 2019-2020 | |
| Amgen INC. | $32.69 | 2019 | |
| Sumitomo Pharma America, INC. | $24.03 | 2023 | Myfembree |
| Exeltis, USA INC. | $21.97 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $19.91 | 2019 | |
| Renovia INC | $13.45 | 2019 | |
| Agile Therapeutics, INC. | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smita Biswas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.